Company Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors.
It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products.
Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Country | Israel |
| Founded | 1993 |
| IPO Date | Aug 11, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Anat Cohen-Dayag |
Contact Details
Address: Azrieli Center, Building D Holon, 5885849 Israel | |
| Phone | 972 3 765 8585 |
| Website | cgen.com |
Stock Details
| Ticker Symbol | CGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001119774 |
| CUSIP Number | M25722105 |
| ISIN Number | IL0010852080 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anat Cohen-Dayag Ph.D. | Chief Executive Officer, President and Director |
| Dr. Eran Ophir Ph.D. | Chief Scientific Officer |
| Dr. Zurit Levine Ph.D. | Senior Vice President of Strategic Collaborations |
| Dr. Pierre Ferre Ph.D. | Senior Vice President of Preclinical Development and Corporate Operations |
| Michelle Mahler M.D. | Chief Medical Officer |
| David Silberman CPA | Chief Financial Officer |
| Yvonne Naughton | Head of Investor Relations and Corporate Communications |
| Eran Ben Dor | General Counsel and Corporate Secretary |
| Dorit Amitay | Vice President of Human Resources |
| Dr. Yaron Turpaz M.B.A., Ph.D. | Senior Vice President and Senior Advisor of Data and Informatics Solutions |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 4, 2025 | 6-K | Report of foreign issuer |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Jan 8, 2025 | 6-K | Report of foreign issuer |
| Nov 27, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 5, 2024 | 6-K | Report of foreign issuer |
| Sep 13, 2024 | 6-K | Report of foreign issuer |
| Aug 6, 2024 | 6-K | Report of foreign issuer |
| Aug 5, 2024 | 6-K | Report of foreign issuer |